Quote:Oops! Republican Senator’s article tells of phantom meeting with Obama nominee
LOL! It's no surprise when a Repug exhibits close mindedness or hypocrisy, but it a real treat when they're caught combining the two so blatantly. Well done Orrin.
By Reuters on Sat, May 28th, 2016 at 7:06 pm
Republican U.S. Senator Orrin Hatch wrote in an opinion piece that his meeting with Merrick Garland failed to change his view that the Senate should not act on President Barack Obama's U.S. Supreme Court nominee. The problem is that no such meeting had yet taken place.
“Hatch helped break a partisan log jam in the Senate against Garland two decades ago when President Bill Clinton nominated him to an appeals court. Garland won Senate confirmation in 1997.”
By Lawrence Hurley
WASHINGTON (Reuters) – Republican U.S. Senator Orrin Hatch wrote in an opinion piece published on Thursday that his meeting with Merrick Garland failed to change his view that the Senate should not act on President Barack Obama’s U.S. Supreme Court nominee.
The problem is that no such meeting had yet taken place. Later in the day, the Utah senator issued a statement announcing that he would meet with Garland on Thursday, calling the appeals court judge “an honorable public servant who deserves our respect” but reiterating that the Senate should not act now.
Paul Edwards, executive editor of the Deseret News in Hatch’s home state of Utah, said by email the article was a draft that was mistakenly published on newspaper’s website, and apologized to Hatch and the newspaper’s readers for “this unfortunate error.”
“Like many of my Senate colleagues, I recently met with Chief Judge Merrick Garland,” Hatch wrote in the piece.
“Our meeting, however, does not change my conviction that the Senate should consider a Supreme Court nominee after this presidential election cycle,” Hatch added.
The 82-year-old Hatch, first elected to the Senate in 1976, is the longest-serving Senate Republican and is a long-time and influential member of the Judiciary Committee that considers Supreme Court nominees.
Hatch has joined with the Senate’s Republican leaders in asserting that Obama’s successor, to be determined in the Nov. 8 presidential election, should fill the vacancy left by the death of conservative Justice Antonin Scalia in February.
Democrats have accused Senate Republicans of ignoring their constitutional duties by refusing to consider Garland’s nomination.
A copy of the article was archived by Google after the Deseret News removed it. “The electronic publication of this version, awaiting edits from the Senator following his meeting with Judge Garland, was inadvertent,” Edwards added.
The article illustrated how unshakeable Republican opposition has been to Obama, a Democrat, appointing a replacement for Scalia. If a Democratic president appoints Scalia’s replacement, that would likely end decades of a conservative majority on the court.
Obama nominated Garland on March 16.
Hatch helped break a partisan log jam in the Senate against Garland two decades ago when President Bill Clinton nominated him to an appeals court. Garland won Senate confirmation in 1997.
Orrin Hatch once said there was “no question” Merrick Garland could be confirmed to the Supreme Court.
Hatch is one of the most respected U.S. senators and has served as chairman of the Senate Judiciary Committee on three separate occasions. Hatch has also been an outspoken advocate of the Republican strategy to wait to confirm a Supreme Court nominee until after the presidential election in November, recently telling the Federalist Society that this was “the chickens coming home to roost” for the Obama Administration.
But Hatch has also been a long-time advocate for Merrick Garland, who President Obama will nominate to the Supreme Court on Wednesday.
In 2010, when he was considered for the slot that ultimately went to Elena Kagan, Hatch said that he had known Garland for years. He added that, if nominated, he would be a “consensus nominee” and that there was “no question” he would be confirmed.
And just last week, he praised Garland and indicated he was a qualified candidate, saying, “The president told me several times he’s going to name a moderate [to fill the court vacancy], but I don’t believe him. [Obama] could easily name Merrick Garland, who is a fine man. He probably won’t do that because this appointment is about the election. So I’m pretty sure he’ll name someone the [liberal Democratic base] wants.”
By nominating Garland, Obama has put Republicans like Hatch on their back foot. They’ll argue that this is about process—about waiting for the American people to decide. Obama’s nomination of Garland is a transparently political maneuver that shows just how transparently political his opponents are being.
Oops! Republican Senator’s article tells of phantom
Top 10 Most Recent News Articles
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart
A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...
Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub
Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...
Continue Reading
Uber Data Breach: Class Action Investigation Begins
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
WeFetch AI: A New Era in Barcode Precision
WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...
Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026
Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...
Continue Reading